Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 42 results for "novartis"

Novartis India standalone net profit rises 17.60% in the September 2017 quarter
Business Standard

Novartis India Q2 net up 18% at Rs 26 crore

Drug firm Novartis India today reported a 17.60 per cent rise in its net profit to Rs 26.12 crore for the quarter ended September 30, 2017.The company had posted a net profit of Rs 22.21 crore for the corresponding period of the previous fiscal, Novartis ... Business Standard, 1 month ago

21 images for novartis

Business Standard, 3 weeks ago, 1 month ago, 1 month ago
Business Standard, 1 month ago
Business Standard, 1 month ago
Money Control, 2 months ago
Money Control, 3 months ago
MSN India, 3 months ago
MSN India, 3 months ago
DNA, 3 months ago

Novartis India fixes record date for buyback of shares

Record date is 08 December 2017 Novartis India has fixed 08 December 2017 as record date for buyback of shares.Powered by Capital Market - Live News (This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.) ...
 Business Standard3 weeks ago Novartis India to buy back shares worth over Rs 231 cr  SME Times2 months ago Novartis India board clears share buyback worth Rs 231 cr  Business Standard2 months ago Novartis India slips 8% as buyback price disappoints  Business Standard2 months ago
Business Standard

Ranjit Shahani steps down at Novartis after two decades

The face of MNC drug firms in India and champion of IPR protection, he oversaw the Swiss giant's India expansion, its forays into new therapies and setting up of its global service centre in Hyderabad Aneesh Phadnis | Mumbai Last Updated at November 13, 2017 ...
 Business Standard1 month ago After 15 years, Ranjit Shahani steps down as Novartis' India chief  Rediff.com1 month ago
Money Control

Novartis India#39;s board meeting held on November 10, 2017

We would like to inform you that the meeting of the Board of Directors of the Company is scheduled to be held on Friday, November 10, 2017.
 Money Control2 months ago Novartis India surges 7% as board mulls share buyback  Business Standard2 months ago Novartis India jumps as board to consider buyback proposal  Business Standard2 months ago

Novartis generics arm says may sell or end some products

ZURICH (Reuters) - Swiss drugmaker Novartis's Sandoz generics business is in the process of selling or closing some products in the United States, it said on Wednesday.
 Reuters1 day ago Novartis to shut U.S. generics plant, cut 450 jobs  Reuters1 month ago

Novartis CAR-T therapy leads to durable response in lymphoma study

(Reuters) - Patients with an advanced form of an aggressive blood cancer who had initially responded to Novartis' new type of gene-modifying immunotherapy continued to respond at least six months after treatment, according to updated data released at a ...
 Reuters4 days ago

Australian watchdog takes GlaxoSmithKline, Novartis units to court

(Reuters) - The Australian Competition and Consumer Commission (ACCC) on Wednesday said it is taking local units of GlaxoSmithKline and Swiss healthcare company Novartis to court over false or misleading representations in the marketing of pain relief ...
 Reuters1 week ago

Novartis gets FDA breakthrough status for Tafinlar, Mekinist combination

Novartis on Monday said the U.S. Food and Drug Administration has granted breakthrough therapy status to the combination of Tafinlar and Mekinist to treat patients with BRAF V600-positive stage III melanoma following surgery. FILE PHOTO - A Novartis logo is ...
 Reuters1 month ago

Novartis says ‍revolade shows long-term disease control for chronic/persistent immune thrombocytopenia​

ZURICH (Reuters) - Novartis said on Wednesday a long term study of ‍its Revolade drug showed good results in treating chronic and persistent immune thrombocytopenia (ITP) - a condition where patients' blood does not clot normally.
 Reuters1 month ago
Business Standard

Novartis to buy France's Advanced Accelerator for $3.9 billion

deal to strengthen the oncology portfolio at the world's biggest maker of prescription medicines. Basel-based Novartis's offer of $41 per ordinary share and $82 per American depositary share represents a 47 percent premium to AAA's price before media reports ...
 Business Standard1 month ago Novartis to buy French cancer specialist AAA for $3.9 billion  Reuters1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less